Switch to:
Also traded in: Germany, Switzerland

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 8/10

vs
industry
vs
history
Cash to Debt 2.00
EW's Cash to Debt is ranked lower than
52% of the 320 Companies
in the Global Medical Devices industry.

( Industry Median: 2.26 vs. EW: 2.00 )
Ranked among companies with meaningful Cash to Debt only.
EW' s Cash to Debt Range Over the Past 10 Years
Min: 0  Med: 1.1 Max: N/A
Current: 2
Equity to Asset 0.62
EW's Equity to Asset is ranked lower than
51% of the 298 Companies
in the Global Medical Devices industry.

( Industry Median: 0.63 vs. EW: 0.62 )
Ranked among companies with meaningful Equity to Asset only.
EW' s Equity to Asset Range Over the Past 10 Years
Min: 0.37  Med: 0.6 Max: 0.74
Current: 0.62
0.37
0.74
Interest Coverage 82.11
EW's Interest Coverage is ranked higher than
51% of the 221 Companies
in the Global Medical Devices industry.

( Industry Median: 71.73 vs. EW: 82.11 )
Ranked among companies with meaningful Interest Coverage only.
EW' s Interest Coverage Range Over the Past 10 Years
Min: 16.5  Med: 63.1 Max: 118.46
Current: 82.11
16.5
118.46
F-Score: 8
Z-Score: 10.42
M-Score: -2.03
WACC vs ROIC
8.92%
31.36%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 9/10

vs
industry
vs
history
Operating margin (%) 27.21
EW's Operating margin (%) is ranked higher than
95% of the 303 Companies
in the Global Medical Devices industry.

( Industry Median: 2.77 vs. EW: 27.21 )
Ranked among companies with meaningful Operating margin (%) only.
EW' s Operating margin (%) Range Over the Past 10 Years
Min: 13.99  Med: 20.5 Max: 53.09
Current: 27.21
13.99
53.09
Net-margin (%) 19.24
EW's Net-margin (%) is ranked higher than
92% of the 303 Companies
in the Global Medical Devices industry.

( Industry Median: 2.25 vs. EW: 19.24 )
Ranked among companies with meaningful Net-margin (%) only.
EW' s Net-margin (%) Range Over the Past 10 Years
Min: 10.36  Med: 15.21 Max: 34.92
Current: 19.24
10.36
34.92
ROE (%) 22.27
EW's ROE (%) is ranked higher than
90% of the 301 Companies
in the Global Medical Devices industry.

( Industry Median: 1.47 vs. EW: 22.27 )
Ranked among companies with meaningful ROE (%) only.
EW' s ROE (%) Range Over the Past 10 Years
Min: 14.26  Med: 19.41 Max: 43.42
Current: 22.27
14.26
43.42
ROA (%) 13.67
EW's ROA (%) is ranked higher than
91% of the 324 Companies
in the Global Medical Devices industry.

( Industry Median: 0.44 vs. EW: 13.67 )
Ranked among companies with meaningful ROA (%) only.
EW' s ROA (%) Range Over the Past 10 Years
Min: 8.72  Med: 12.97 Max: 26.03
Current: 13.67
8.72
26.03
ROC (Joel Greenblatt) (%) 87.13
EW's ROC (Joel Greenblatt) (%) is ranked higher than
93% of the 320 Companies
in the Global Medical Devices industry.

( Industry Median: 4.32 vs. EW: 87.13 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
EW' s ROC (Joel Greenblatt) (%) Range Over the Past 10 Years
Min: 41.35  Med: 53.39 Max: 138.73
Current: 87.13
41.35
138.73
Revenue Growth (3Y)(%) 12.10
EW's Revenue Growth (3Y)(%) is ranked higher than
77% of the 229 Companies
in the Global Medical Devices industry.

( Industry Median: 3.80 vs. EW: 12.10 )
Ranked among companies with meaningful Revenue Growth (3Y)(%) only.
EW' s Revenue Growth (3Y)(%) Range Over the Past 10 Years
Min: -9.7  Med: 11.05 Max: 15.1
Current: 12.1
-9.7
15.1
EBITDA Growth (3Y)(%) 19.30
EW's EBITDA Growth (3Y)(%) is ranked higher than
74% of the 196 Companies
in the Global Medical Devices industry.

( Industry Median: 2.80 vs. EW: 19.30 )
Ranked among companies with meaningful EBITDA Growth (3Y)(%) only.
EW' s EBITDA Growth (3Y)(%) Range Over the Past 10 Years
Min: -20.2  Med: 17.2 Max: 57.8
Current: 19.3
-20.2
57.8
EPS Growth (3Y)(%) 22.30
EW's EPS Growth (3Y)(%) is ranked higher than
76% of the 197 Companies
in the Global Medical Devices industry.

( Industry Median: 2.40 vs. EW: 22.30 )
Ranked among companies with meaningful EPS Growth (3Y)(%) only.
EW' s EPS Growth (3Y)(%) Range Over the Past 10 Years
Min: 0  Med: 21.8 Max: 288.2
Current: 22.3
0
288.2
GuruFocus has detected 1 Warning Sign with Edwards Lifesciences Corp $EW.
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
» EW's 10-Y Financials

Financials (Next Earnings Date: 2017-02-01)


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow
Oprt. Cash Flow & Net Income

» Details

Guru Trades

Q4 2015

EW Guru Trades in Q4 2015

Frank Sands 10,924,382 sh (+724.24%)
Pioneer Investments 1,578,222 sh (+679.04%)
Jim Simons 1,105,100 sh (+205.86%)
Paul Tudor Jones 9,847 sh (+117.42%)
John Hussman 50,000 sh (+100.00%)
PRIMECAP Management 560,000 sh (+100.00%)
Ron Baron 664,199 sh (+87.82%)
RS Investment Management 168,325 sh (+77.59%)
Jeremy Grantham 215,118 sh (+72.62%)
Vanguard Health Care Fund 3,217,520 sh (+36.80%)
Louis Moore Bacon 120,000 sh (+18.44%)
Steven Cohen 145,400 sh (unchged)
Joel Greenblatt Sold Out
Steven Cohen 149,800 sh (-35.76%)
» More
Q1 2016

EW Guru Trades in Q1 2016

Ray Dalio 18,800 sh (New)
Jim Simons 1,665,800 sh (+50.74%)
Pioneer Investments 1,716,295 sh (+8.75%)
RS Investment Management 182,175 sh (+8.23%)
John Hussman 50,000 sh (unchged)
PRIMECAP Management 560,000 sh (unchged)
Louis Moore Bacon Sold Out
Vanguard Health Care Fund Sold Out
Frank Sands 10,172,988 sh (-6.88%)
Ron Baron 528,665 sh (-20.41%)
Jeremy Grantham 149,328 sh (-30.58%)
Paul Tudor Jones 2,600 sh (-73.60%)
Steven Cohen 13,700 sh (-90.85%)
» More
Q2 2016

EW Guru Trades in Q2 2016

Louis Moore Bacon 2,323 sh (New)
Joel Greenblatt 5,837 sh (New)
Lee Ainslie 32,300 sh (New)
Samuel Isaly 175,800 sh (New)
Steven Cohen 194,200 sh (+1317.52%)
Paul Tudor Jones 16,686 sh (+541.77%)
Ray Dalio 33,800 sh (+79.79%)
Jim Simons 2,213,800 sh (+32.90%)
PRIMECAP Management 560,000 sh (unchged)
John Hussman 50,000 sh (unchged)
Jeremy Grantham Sold Out
Pioneer Investments 1,703,864 sh (-0.72%)
Frank Sands 9,619,255 sh (-5.44%)
RS Investment Management 91,090 sh (-50.00%)
Ron Baron 30,903 sh (-94.15%)
» More
Q3 2016

EW Guru Trades in Q3 2016

Steven Cohen 337,900 sh (+74.00%)
Louis Moore Bacon 3,570 sh (+53.68%)
Ray Dalio 45,065 sh (+33.33%)
Pioneer Investments 1,762,534 sh (+3.44%)
Samuel Isaly 213,257 sh (+21.31%)
John Hussman 50,000 sh (unchged)
PRIMECAP Management 560,000 sh (unchged)
Paul Tudor Jones Sold Out
Joel Greenblatt Sold Out
Frank Sands 9,035,637 sh (-6.07%)
Lee Ainslie 26,900 sh (-16.72%)
Jim Simons 1,476,406 sh (-33.31%)
Ron Baron 10,762 sh (-65.17%)
» More
» Details

Insider Trades

Latest Guru Trades with EW

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Medical Devices » Medical Devices    NAICS: 339113    SIC: 3842
Compare:NYSE:ZBH, NAS:ISRG, OTCPK:SNNUF, NYSE:BSX, NYSE:VAR, OTCPK:SONVY, NAS:ALGN, NYSE:TFX, OTCPK:CHEOY, NAS:ABMD, OTCPK:WILLF, NAS:NUVA, OTCPK:EKTAY, NAS:MASI, NAS:IART, NYSE:GMED, NAS:WMGI, NYSE:NVRO, NAS:LIVN, NYSE:PEN » details
Traded in other countries:EWL.Germany, EW.Switzerland,
Edwards Lifesciences Corp technologies that treat structural heart disease and critically ill patients. It manufactures heart valves and repair products used to replace or repair a patient's diseased or defective heart valve.

Edwards Lifesciences Corp was incorporated in Delaware on September 10, 1999. The Company is the manufacturer of heart valves and repair products used to replace or repair a patient's diseased or defective heart valve. It is also a leader in hemodynamic monitoring systems used to measure a patient's cardiovascular function in the hospital setting. It conducts operations all over world and is managed in the following geographical regions: United States, Europe, Japan and Rest of World. The products and technologies provided by the Company to treat cardiovascular disease or critically ill patients are categorized into the following main areas: Surgical Heart Valve Therapy, Transcatheter Heart Valves, and Critical Care. The Company's Surgical Heart Valve Therapy portfolio includes tissue heart valves and heart valve repair products for the surgical replacement or repair of a patient's heart valve. The portfolio also includes a diverse line of cardiac surgery systems used during minimally invasive surgical procedures, and cannulae, embolic protection devices and other products used during cardiopulmonary bypass. The Company's Transcatheter Heart Valves portfolio includes technologies designed to treat heart valve disease using catheter-based approaches as opposed to open surgical techniques. In the Critical Care portfolio, Edwards Lifesciences' products include pulmonary artery catheters, disposable pressure transducers and monitoring systems. The portfolio also includes a line of balloon catheter-based vascular products, surgical clips and inserts. The Company competes with many companies, including divisions of companies much larger than it and smaller companies that compete in specific product lines or certain geographies. The Company's Surgical Heart Valve Therapy and Transcatheter Heart Valve products are manufactured in California and Utah in the United States, Switzerland, and Singapore. Critical Care products are manufactured in its facilities located in Puerto Rico and the Dominican Republic. The Company's products and technologies are subject to regulation by numerous domestic and foreign government agencies, including the FDA, and various laws and regulations governing the development, testing, manufacturing, labeling, marketing and distribution of its products and technologies.

Top Ranked Articles about Edwards Lifesciences Corp

Numerous Companies Reach Yearly Highs Recently, a handful of companies achieved 52-week highs
According to GuruFocus list of 52-week highs, these stocks have reached their 52-week highs. Read more...
Vanguard Sells Out Edwards Lifesciences Company's price and P/E ratio near 10-year highs
Vanguard Heath Care Fund sold out its stake in Edwards Lifesciences Corp. (NYSE:EW) in the first quarter. Read more...
Sands Capital Boosts Stake in Edwards Lifesciences Sands Capital buys nearly 9.6 million shares in 4th quarter
Frank Sands' Sands Capital Management boosted its stake in Edwards Lifesciences (NYSE:EW) in the fourth quarter by adding 9,598,997 shares. Read more...

Ratios

vs
industry
vs
history
P/E(ttm) 38.35
EW's P/E(ttm) is ranked lower than
65% of the 172 Companies
in the Global Medical Devices industry.

( Industry Median: 26.07 vs. EW: 38.35 )
Ranked among companies with meaningful P/E(ttm) only.
EW' s P/E(ttm) Range Over the Past 10 Years
Min: 11.18  Med: 27.85 Max: 50.58
Current: 38.35
11.18
50.58
Forward P/E 28.57
EW's Forward P/E is ranked lower than
66% of the 56 Companies
in the Global Medical Devices industry.

( Industry Median: 24.39 vs. EW: 28.57 )
Ranked among companies with meaningful Forward P/E only.
N/A
PE(NRI) 38.35
EW's PE(NRI) is ranked lower than
64% of the 173 Companies
in the Global Medical Devices industry.

( Industry Median: 25.71 vs. EW: 38.35 )
Ranked among companies with meaningful PE(NRI) only.
EW' s PE(NRI) Range Over the Past 10 Years
Min: 11.16  Med: 27.71 Max: 49.62
Current: 38.35
11.16
49.62
Price/Owner Earnings (ttm) 44.52
EW's Price/Owner Earnings (ttm) is ranked lower than
67% of the 110 Companies
in the Global Medical Devices industry.

( Industry Median: 31.72 vs. EW: 44.52 )
Ranked among companies with meaningful Price/Owner Earnings (ttm) only.
EW' s Price/Owner Earnings (ttm) Range Over the Past 10 Years
Min: 7.88  Med: 33.5 Max: 572.5
Current: 44.52
7.88
572.5
P/B 7.68
EW's P/B is ranked lower than
80% of the 297 Companies
in the Global Medical Devices industry.

( Industry Median: 3.17 vs. EW: 7.68 )
Ranked among companies with meaningful P/B only.
EW' s P/B Range Over the Past 10 Years
Min: 2.9  Med: 5.45 Max: 10.16
Current: 7.68
2.9
10.16
P/S 7.37
EW's P/S is ranked lower than
79% of the 286 Companies
in the Global Medical Devices industry.

( Industry Median: 3.08 vs. EW: 7.37 )
Ranked among companies with meaningful P/S only.
EW' s P/S Range Over the Past 10 Years
Min: 2.32  Med: 4.56 Max: 9.41
Current: 7.37
2.32
9.41
PFCF 51.40
EW's PFCF is ranked lower than
74% of the 107 Companies
in the Global Medical Devices industry.

( Industry Median: 27.61 vs. EW: 51.40 )
Ranked among companies with meaningful PFCF only.
EW' s PFCF Range Over the Past 10 Years
Min: 7.83  Med: 37.69 Max: 593.7
Current: 51.4
7.83
593.7
POCF 34.85
EW's POCF is ranked lower than
77% of the 134 Companies
in the Global Medical Devices industry.

( Industry Median: 18.89 vs. EW: 34.85 )
Ranked among companies with meaningful POCF only.
EW' s POCF Range Over the Past 10 Years
Min: 7.34  Med: 24.76 Max: 48.74
Current: 34.85
7.34
48.74
EV-to-EBIT 25.70
EW's EV-to-EBIT is ranked lower than
58% of the 166 Companies
in the Global Medical Devices industry.

( Industry Median: 21.95 vs. EW: 25.70 )
Ranked among companies with meaningful EV-to-EBIT only.
EW' s EV-to-EBIT Range Over the Past 10 Years
Min: 6.8  Med: 20.1 Max: 39.7
Current: 25.7
6.8
39.7
EV-to-EBITDA 23.70
EW's EV-to-EBITDA is ranked lower than
68% of the 178 Companies
in the Global Medical Devices industry.

( Industry Median: 16.63 vs. EW: 23.70 )
Ranked among companies with meaningful EV-to-EBITDA only.
EW' s EV-to-EBITDA Range Over the Past 10 Years
Min: 6.4  Med: 15.9 Max: 33.5
Current: 23.7
6.4
33.5
PEG 1.37
EW's PEG is ranked higher than
70% of the 74 Companies
in the Global Medical Devices industry.

( Industry Median: 2.40 vs. EW: 1.37 )
Ranked among companies with meaningful PEG only.
EW' s PEG Range Over the Past 10 Years
Min: 0.45  Med: 1.37 Max: 3.46
Current: 1.37
0.45
3.46
Shiller P/E 62.79
EW's Shiller P/E is ranked lower than
63% of the 48 Companies
in the Global Medical Devices industry.

( Industry Median: 48.71 vs. EW: 62.79 )
Ranked among companies with meaningful Shiller P/E only.
EW' s Shiller P/E Range Over the Past 10 Years
Min: 34.67  Med: 62.6 Max: 124.24
Current: 62.79
34.67
124.24
Current Ratio 4.08
EW's Current Ratio is ranked higher than
71% of the 320 Companies
in the Global Medical Devices industry.

( Industry Median: 2.45 vs. EW: 4.08 )
Ranked among companies with meaningful Current Ratio only.
EW' s Current Ratio Range Over the Past 10 Years
Min: 0.89  Med: 2.67 Max: 5.56
Current: 4.08
0.89
5.56
Quick Ratio 3.32
EW's Quick Ratio is ranked higher than
73% of the 320 Companies
in the Global Medical Devices industry.

( Industry Median: 1.79 vs. EW: 3.32 )
Ranked among companies with meaningful Quick Ratio only.
EW' s Quick Ratio Range Over the Past 10 Years
Min: 0.49  Med: 2.09 Max: 4.83
Current: 3.32
0.49
4.83
Days Inventory 172.74
EW's Days Inventory is ranked lower than
67% of the 284 Companies
in the Global Medical Devices industry.

( Industry Median: 131.45 vs. EW: 172.74 )
Ranked among companies with meaningful Days Inventory only.
EW' s Days Inventory Range Over the Past 10 Years
Min: 132.4  Med: 169.19 Max: 208.39
Current: 172.74
132.4
208.39
Days Sales Outstanding 57.82
EW's Days Sales Outstanding is ranked higher than
65% of the 270 Companies
in the Global Medical Devices industry.

( Industry Median: 67.65 vs. EW: 57.82 )
Ranked among companies with meaningful Days Sales Outstanding only.
EW' s Days Sales Outstanding Range Over the Past 10 Years
Min: 38.74  Med: 54.46 Max: 69.95
Current: 57.82
38.74
69.95
Days Payable 41.78
EW's Days Payable is ranked lower than
64% of the 253 Companies
in the Global Medical Devices industry.

( Industry Median: 56.36 vs. EW: 41.78 )
Ranked among companies with meaningful Days Payable only.
EW' s Days Payable Range Over the Past 10 Years
Min: 33.96  Med: 51.13 Max: 63.34
Current: 41.78
33.96
63.34

Buy Back

vs
industry
vs
history
3-Year Average Share Buyback Ratio 2.00
EW's 3-Year Average Share Buyback Ratio is ranked higher than
93% of the 206 Companies
in the Global Medical Devices industry.

( Industry Median: -3.90 vs. EW: 2.00 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
EW' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -1.2  Med: 0.45 Max: 2.2
Current: 2
-1.2
2.2

Valuation & Return

vs
industry
vs
history
Price/Net Current Asset Value 39.30
EW's Price/Net Current Asset Value is ranked lower than
91% of the 203 Companies
in the Global Medical Devices industry.

( Industry Median: 6.60 vs. EW: 39.30 )
Ranked among companies with meaningful Price/Net Current Asset Value only.
EW' s Price/Net Current Asset Value Range Over the Past 10 Years
Min: 10.47  Med: 17.1 Max: 568
Current: 39.3
10.47
568
Price/Tangible Book 11.09
EW's Price/Tangible Book is ranked lower than
80% of the 264 Companies
in the Global Medical Devices industry.

( Industry Median: 4.35 vs. EW: 11.09 )
Ranked among companies with meaningful Price/Tangible Book only.
EW' s Price/Tangible Book Range Over the Past 10 Years
Min: 5.58  Med: 9.81 Max: 199.7
Current: 11.09
5.58
199.7
Price/Projected FCF 2.43
EW's Price/Projected FCF is ranked lower than
61% of the 126 Companies
in the Global Medical Devices industry.

( Industry Median: 2.02 vs. EW: 2.43 )
Ranked among companies with meaningful Price/Projected FCF only.
EW' s Price/Projected FCF Range Over the Past 10 Years
Min: 1.36  Med: 1.95 Max: 3.62
Current: 2.43
1.36
3.62
Price/DCF (Earnings Based) 1.34
EW's Price/DCF (Earnings Based) is ranked higher than
83% of the 18 Companies
in the Global Medical Devices industry.

( Industry Median: 2.17 vs. EW: 1.34 )
Ranked among companies with meaningful Price/DCF (Earnings Based) only.
N/A
Price/Median PS Value 1.61
EW's Price/Median PS Value is ranked lower than
81% of the 231 Companies
in the Global Medical Devices industry.

( Industry Median: 1.01 vs. EW: 1.61 )
Ranked among companies with meaningful Price/Median PS Value only.
EW' s Price/Median PS Value Range Over the Past 10 Years
Min: 0.21  Med: 0.65 Max: 2.01
Current: 1.61
0.21
2.01
Price/Peter Lynch Fair Value 1.52
EW's Price/Peter Lynch Fair Value is ranked higher than
55% of the 51 Companies
in the Global Medical Devices industry.

( Industry Median: 1.62 vs. EW: 1.52 )
Ranked among companies with meaningful Price/Peter Lynch Fair Value only.
EW' s Price/Peter Lynch Fair Value Range Over the Past 10 Years
Min: 0.59  Med: 1.41 Max: 3.25
Current: 1.52
0.59
3.25
Price/Graham Number 4.33
EW's Price/Graham Number is ranked lower than
75% of the 138 Companies
in the Global Medical Devices industry.

( Industry Median: 2.32 vs. EW: 4.33 )
Ranked among companies with meaningful Price/Graham Number only.
EW' s Price/Graham Number Range Over the Past 10 Years
Min: 1.81  Med: 3.47 Max: 29.59
Current: 4.33
1.81
29.59
Earnings Yield (Greenblatt) (%) 3.90
EW's Earnings Yield (Greenblatt) (%) is ranked higher than
69% of the 308 Companies
in the Global Medical Devices industry.

( Industry Median: 1.00 vs. EW: 3.90 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
EW' s Earnings Yield (Greenblatt) (%) Range Over the Past 10 Years
Min: 2.5  Med: 5 Max: 14.7
Current: 3.9
2.5
14.7
Forward Rate of Return (Yacktman) (%) 28.41
EW's Forward Rate of Return (Yacktman) (%) is ranked higher than
91% of the 122 Companies
in the Global Medical Devices industry.

( Industry Median: 8.85 vs. EW: 28.41 )
Ranked among companies with meaningful Forward Rate of Return (Yacktman) (%) only.
EW' s Forward Rate of Return (Yacktman) (%) Range Over the Past 10 Years
Min: 15  Med: 22.6 Max: 37.4
Current: 28.41
15
37.4

More Statistics

Revenue (TTM) (Mil) $2,867
EPS (TTM) $ 2.53
Beta0.90
Short Percentage of Float1.45%
52-Week Range $72.20 - 121.75
Shares Outstanding (Mil)213.81

Analyst Estimate

Dec16 Dec17 Dec18 Dec19
Revenue (Mil $) 2,950 3,282 3,656 3,814
EPS ($) 2.81 3.40 3.97 4.12
EPS w/o NRI ($) 2.81 3.40 3.97 4.12
EPS Growth Rate
(3Y to 5Y Estimate)
16.22%
Dividends Per Share ($)
» More Articles for NYSE:EW

Headlines

Articles On GuruFocus.com
Weekly Top Insider Buys Highlight for the Week of Dec. 2 Dec 04 2016 
Medtronic Misses 2nd Quarter Revenue Expectations Nov 27 2016 
Numerous Companies Reach Yearly Highs Oct 03 2016 
7 Stocks with Strong Returns and Profitability Aug 04 2016 
Sam Isaly's Top Investments of the Year Aug 01 2016 
Johnson & Johnson Reports 4% Sales Growth for the Second Quarter Jul 22 2016 
Opinions Differ on Abbott Deal to Acquire St. Jude's Medical Jun 18 2016 
Vanguard Sells Out Edwards Lifesciences May 03 2016 
Sands Capital Boosts Stake in Edwards Lifesciences Mar 09 2016 
Frank Sands Acquires Stake in Netflix Feb 23 2016 

More From Other Websites
Edward Lifesciences (EW): What's in Store in Q4 Earnings? Jan 18 2017
Edwards Lifesciences To Host Earnings Conference Call On February 1, 2017 Jan 17 2017
Cramer’s exec cut: The secret to competing with Amazon in... Jan 13 2017
Edwards Lifesciences Is Recovering From a Bearish Gap Jan 11 2017
Medtronic Downgraded On Increased Boston, J&J, St. Jude Rivalries Jan 03 2017
Edwards Lifesciences To Present At The 35th Annual J.P. Morgan Healthcare Conference Jan 03 2017
Edwards Lifesciences upgraded by Guggenheim Jan 03 2017
Edwards Lifesciences Corp. – Value Analysis (NYSE:EW) : December 27, 2016 Dec 27 2016
Edwards Lifesciences Corp. breached its 50 day moving average in a Bullish Manner : EW-US : December... Dec 26 2016
Inside Edwards Lifesciences’ Financial Guidance for 2017 Dec 20 2016
These 5 Health Care Stocks Are Breaking Out This Christmas Dec 20 2016
Understanding the Key Drivers of EW’s Critical Care Business Growth Dec 19 2016
Where Is EW’s SHV Therapy Segment Headed after Disappointing 3Q16 Sales? Dec 19 2016
Edwards Lifesciences’ Acquisition of Valtech Cardio: Must-Know Details Dec 19 2016
New Structural Heart Initiatives: Edwards’ Key Growth Drivers in 2017 and Beyond Dec 16 2016
Inside Edwards Lifesciences’ THV Product Pipeline and Future Growth Estimates Dec 16 2016
Edwards Lifesciences Riding High on TAVR Sales Growth and Future Opportunities Dec 16 2016
Edwards Lifesciences Sees Growth on Long-Term Growth Strategy Dec 15 2016
Is Edwards Lifesciences Stock Recovering from Its Recent Declining Trend? Dec 15 2016
The Word on the Street: What Analysts Are Recommending for Edwards Lifesciences Now Dec 15 2016

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)